Breaking News

Galapagos to Acquire CellPoint and AboundBio

Gains scalable, decentralized and automated point-of-care cell therapy supply model and next-gen fully human antibody-based therapeutics platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Galapagos NV has entered agreements to acquire CellPoint and AboundBio, advancing Galapagos into next-generation cell therapy and expanding its portfolio and capabilities.   The acquisition of CellPoint and AboundBio provides access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. The goal is to expand the current market for CAR-T therapies and provide additional and im...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters